2021年10月15日简报:若2022年初疫苗接种率能超过85%,中国或有望打开国门;非洲超85%新冠患者未被发现;葡萄牙12岁以上的人中有 98% 接种了疫苗

2021-10-15 MedSci整理 MedSci整理

截至北京时间2021年10月15日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿4033万例,新增405,102例,达到240,338,

截至北京时间2021年10月15日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过2亿4033万例,新增405,102例,达到240,338,368例。累计死亡病例489.6万例,达到4,896,286例。新增死亡为6,814例。康复为217,205,588例,重症和危重症病人达到80,745例;全球新冠确诊病例超过100万例的国家达35个,110个国家病例超10万例。昨日报道:2021年10月14日简报:全球疫情持续缓解,死亡降至近一年来最低水平;部分国家抢先订购新冠口服药,再引分配不均担忧

若2022年初疫苗接种率能超过85%,中国或有望打开国门

时间已经来到了2021年10月,随着新冠疫苗接种进程的加速,全球已经有越来越多的国家开始打开国门。中国国门何时能够打开?也日渐成为旅游业者和百姓们都关心的问题。

就在近日,中国疾病预防控制中心主任高福在接受采访时用一句反问回答了这个问题:中国若争取尽快到2022年初,疫苗接种率能达到85%以上,那就成功了。即便再有感染,一是感染数量少了,二是没有重症和死亡,都是轻症。那到了这时候,“我反过来要问,全球都开放了,病死率降得那么低,我们为什么不开放呢?”

虽然高福没有具体说明打开国门是否意味着减少隔离或者免隔离,但是参照新加坡近日与欧美8国开通的疫苗接种者旅游走廊(Vaccinated Travel Lane)计划,旅客往返这些国家时只要接受新冠肺炎检测,不用隔离。

根据今年发布的第七次全国人口普查结果,2021年中国人口总数是14.43亿,如果按照接种率85%来计算,则大约要有12.3亿人接种。9月18日时,接种总人数就已经超过了11亿人。

世卫组织:非洲超85%新冠患者未被发现

当地时间10月14日,世卫组织非洲区域办事处在刚果(布)首都布拉柴维尔召开在线记者会。根据世卫组织的最新评估数据,目前非洲大陆检测到的新冠确诊病例仅为真实数字的约14.2%,即7个患者中只有1人接受了检测,而其余85%以上的新冠患者并未被发现。

根据发布会的内容,非洲大陆过去一周新增超42000例确诊病例,累计确诊超过840万例,累计死亡病例超214000例。大多数非洲国家对潜在病例追踪的缺失导致新冠病毒的社区传播愈演愈烈,而疫苗接种率又一直处于低位,一些国家的第三波疫情仍处于新增病例激增期。

世卫组织非洲区域主任莫提表示,新冠病毒检测率有限,大多数检测是针对有症状的感染者进行的,但大部分病毒传播是由无症状感染者导致的,大约有65%至85%的病例是无症状感染者。

按照世卫组织的评估,非洲大陆的真实感染病例数可能高达5900万例。为扭转这一情况,世卫组织非洲区域办事处当天宣布了一项计划,将在布隆迪、科特迪瓦、刚果(金)、几内亚比绍、莫桑比克、刚果(布)、塞内加尔和赞比亚等8个非洲国家开展加强新冠肺炎病例社区筛查的项目。该项目将于明年开展,以快速抗原检测为手段覆盖700万人,从而将参与国的检测能力提高40%,以尽快打破病毒传播链。

85%接种率已经成为共同目标

国家旅业网注意到,要想达到群体免疫力,则新冠疫苗接种率需达到85%以上,这基本是目前世界各国疾控机构和疾控专家们的共识

今年7月份,国际在线曾报道,德国疾控机构表示,根据该机构测算结果,若要对德尔塔毒株具有群体免疫力,避免秋季德国出现严重的第四波疫情,该国12-59岁人群疫苗接种率至少应达到85%,60岁以上的人群接种率还应更高。

葡萄牙卫生部近日也发布声明,截至10月9日,葡萄牙大陆已实现85%的人口完全接种Covid-19疫苗的目标。葡萄牙大陆约接种了1530万支疫苗,有840万人已完全接种新冠疫苗。因此,葡萄牙成为世界上第一个达到85%人口接种疫苗目标的国家。

关于12至17岁的青少年,葡萄牙卫生部透露,估计约有88%的青年已经开始了他们的疫苗接种计划,而且,其中83%的人已完成二剂的新冠疫苗接种。

马来西亚成年人口的接种率已经达到90%,因此马来西亚政府决定放宽限制,从10月11日起,所有完成新冠疫苗接种的民众可以在不需要警方申请的情况下跨州。

葡萄牙的新冠疫苗接种率为86%,12岁以上的人中有 98% 接种了疫苗

新冠危机中的葡萄牙已从"问题少年"转身成为到模范生:葡萄牙12岁以上的人中有 98% 接种了疫苗,这是世界绝无仅有的。而成功地推动疫苗接种运动的关键人物是一位海军中将。他解释了自己是如何说服疫苗怀疑论者 ,同时表达了对加强疫苗接种的担心。

10月1日,该国庆祝了自由日,并将冠状病毒限制降至最低:未来,葡萄牙人前往餐馆酒店和上帝可以不戴口罩,也不需要疫苗接种证明。酒吧和迪斯科舞厅也重新开放了。

实际上,7月底以来,该国感染和死亡人数稳步下降,重症监护室的局势不再紧张。

马来西亚疫苗接种率已达90%

马来西亚卫生部公布的数据显示,截至昨天,全马超2130万人完成了新冠疫苗接种,占全国成年人口的90%,占全国总人口的65.2%

数据显示,截至目前,有四个州属的成年人接种率低于80%,包括霹雳79.8%、吉打79.5%、吉兰丹73.6%、沙巴65.1%。

截至目前,马来西亚新冠疫苗接种量累计超过了4565万剂,超过2445万人至少接种了一剂疫苗,占全马总人口的74.9%。

青少年接种疫苗方面,72.2%年龄介于12岁至17岁的青少年至少接种了一剂疫苗,7.4%的青少年完成了疫苗接种。

印尼公布科兴新冠疫苗三临床研究结果:重症保护100%

9月24日,国际疫苗领域期刊《Vaccine》在线发表了题为《一项针对18-59岁健康成年人的新冠病毒灭活疫苗有效性、安全性和免疫原性的观察者盲法、随机、安慰剂对照III期临床研究:印度尼西亚的中期分析》(A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia)的研究论文。

结果显示,接种科兴控股生物技术有限公司旗下北京科兴中维生物技术有限公司研制的新冠灭活疫苗克尔来福安全、有效且疫苗质量稳定。

本次研究共纳入1620名受试者,将其以1:1的比例随机分入疫苗组或安慰剂组,间隔14天(紧急程序)分别接种科兴的新冠灭活疫苗克尔来福或安慰剂,接种后观察第二剂接种后至少14天后的安全性、免疫原性,以及对新冠病毒有症状感染的保护效果。

安全性结果显示:接种克尔来福后,不良事件以轻度为主,接种部位疼痛和肌痛分别为最常见的局部或全身不良事件。

有效性结果显示:接种第二剂克尔来福14天后的有效性为65.3%,疫苗对住院、重症、死亡的保护效果为100%。

免疫原性结果显示:接种第二剂疫苗14天后,特异性免疫球蛋白G(IgG)的血清转化率为97.48%,显著高于安慰剂组(0.75%);中和抗体阳转率为87.15%,安慰剂组未发现中和抗体阳转人员。

拜登:即将发布较大型企业员工新冠疫苗接种令

10月14日,美国总统拜登发表了关于新冠疫情进展的讲话。拜登表示,劳工部将会发布一项紧急规定,要求拥有100名及以上员工的公司,在其员工中实施疫苗接种。据估计,这一计划将影响全美大约8千万员工,占美国全部劳工的一半以上。拜登表示疫苗正在发挥作用,确诊率、住院率均在不断下降。拜登要求所有尚未接种疫苗的人尽快完成接种,同时表示疫苗接种不该成为另一个造成美国分裂的原因。此前,美国多地民众举行游行,反对强制疫苗令

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2022-03-31 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2022-05-23 yaanren
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2021-10-15 向药师

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2021-10-15 铜绿假单包

    85%

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2078676, encodeId=3d5220e86763a, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Thu Mar 31 21:58:55 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906562, encodeId=4a28190656257, content=<a href='/topic/show?id=317e5805e9d' target=_blank style='color:#2F92EE;'>#新冠患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58057, encryptionId=317e5805e9d, topicName=新冠患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Sun Nov 21 03:58:55 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774530, encodeId=83301e74530fb, content=<a href='/topic/show?id=cb4888233f4' target=_blank style='color:#2F92EE;'>#葡萄牙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88233, encryptionId=cb4888233f4, topicName=葡萄牙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4aad38584767, createdName=yaanren, createdTime=Mon May 23 15:58:55 CST 2022, time=2022-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258106, encodeId=2da81258106ae, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Oct 16 22:58:55 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060864, encodeId=f1461060864e1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8be75220179, createdName=向药师, createdTime=Fri Oct 15 21:45:19 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060732, encodeId=a36f1060e3202, content=85%, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210927/683d359ecdf44d6d9ed9c8f175e8fb91/a523fadcaa91467caed3d353cb913a9b.gif, createdBy=a7525619074, createdName=铜绿假单包, createdTime=Fri Oct 15 14:11:55 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060655, encodeId=aa261060655cf, content=已学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c535478465, createdName=ms3000001728230381, createdTime=Fri Oct 15 09:32:39 CST 2021, time=2021-10-15, status=1, ipAttribution=)]
    2021-10-15 ms3000001728230381

    已学习

    0

相关资讯

2021年10月6日简报:美国民众反智,奇葩新冠阴谋论流行,大批民众拒绝接种疫苗;欧洲药品管理局可能开始加速评估默克的新冠口服药;新西兰宣布放弃“彻底消除新冠”战略

截至北京时间2021年10月6日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23655万例,新增394,248例,达到236,554,40

新冠疫苗加强针来了,安全吗?

​随着南京、扬州、郑州等疫情的发生以及新冠病毒的变异,引起了不少人的担心,国药集团中国生物技术股份有限公司已向有关部门提交接种新冠肺炎灭活疫苗第三针加强针的建议。新冠疫苗加强针呼之欲出。

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批:新冠研究新近进展

mRNA疫苗保护力5个月后大幅降低,首款新冠口服药即将获批 | 新冠研究最新进展

2021年10月12日简报:灭活疫苗接种后、以mRNA疫苗加强接种,中和抗体提升46.6倍;日本新冠疫情“退潮”令专家困惑;全国累计报告接种新冠疫苗22.2亿剂次

截至北京时间2021年10月12日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过238971万例,新增295,895例,达到238,971,

2021年10月13日简报:新冠疫苗可将住院风险降低九成;中国疫苗最快年底获欧盟批准!美FDA拒绝推荐Moderna新冠疫苗作为加强针;

截至北京时间2021年10月13日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过2亿3939万例,新增356,863例,达到239,399,

2021年10月7日简报:张文宏认为新冠结束时间已不远!口服药,加强针成为全球重新开放的保障;全球新增新冠确诊病例和死亡人数继续下降

截至北京时间2021年10月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过23701万例,新增413,161例,达到237,010,37